2016
Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research
Schalper KA, Kaftan E, Herbst RS. Predictive Biomarkers for PD-1 Axis Therapies: The Hidden Treasure or a Call for Research. Clinical Cancer Research 2016, 22: 2102-2104. PMID: 26957559, PMCID: PMC4940186, DOI: 10.1158/1078-0432.ccr-16-0169.Peer-Reviewed Original Research
2003
977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer
Herbst R, Mininberg E, Henderson T, Kim E, Hong W, Mass R, Novotny W, Garcia B, Johnson D, Sandler A. 977 Phase I/II trial evaluating blockade of tumour blood supply and tumour cell proliferation with combined bevacizumab and erlotinib HCl as targeted cancer therapy in patients with recurrent non-small cell lung cancer. European Journal Of Cancer Supplements 2003, 1: s293. DOI: 10.1016/s1359-6349(03)91004-4.Peer-Reviewed Original ResearchO-290 Blockade of EGFR tyrosine kinase does not predict outcome in a new orthotopic model of human lung cancer
Onn A, Isobe T, Itasaka S, Wu W, O'Reilly M, Fidler I, Herbst R. O-290 Blockade of EGFR tyrosine kinase does not predict outcome in a new orthotopic model of human lung cancer. Lung Cancer 2003, 41: s84-s85. DOI: 10.1016/s0169-5002(03)91948-9.Peer-Reviewed Original Research